Vishakha Negi is an associate in the Century City office of Wilson Sonsini Goodrich & Rosati, where she is a member of the patents and innovations practice. She focuses on patent prosecution and due diligence matters, primarily in the fields of biotechnology, life sciences, therapeutics, and medical devices.
While pursuing her undergraduate degree at Yale University, Vishakha conducted research on the effect of the degradation of autophagic pathways on neurodegeneration in multiple sclerosis. During law school, she served as a judicial extern to Judge Gonzalo P. Curiel of the United States District Court for the Southern District of California. She also worked as a scientific advisor and patent agent with the firm during law school.
Vishakha is fluent in Hindi.
Vishakha Negi is an associate in the Century City office of Wilson Sonsini Goodrich & Rosati, where she is a member of the patents and innovations practice. She focuses on patent prosecution and due diligence matters, primarily in the fields of biotechnology, life sciences, therapeutics, and medical devices.
While pursuing her undergraduate degree at Yale University, Vishakha conducted research on the effect of the degradation of autophagic pathways on neurodegeneration in multiple sclerosis. During law school, she served as a judicial extern to Judge Gonzalo P. Curiel of the United States District Court for the Southern District of California. She also worked as a scientific advisor and patent agent with the firm during law school.
Vishakha is fluent in Hindi.
- J.D., UCLA School of Law, 2021
- B.S., Molecular, Cellular, and Developmental Biology and History, Yale University, 2017
- State Bar of California
- U.S. Patent and Trademark Office
- J.D., UCLA School of Law, 2021
- B.S., Molecular, Cellular, and Developmental Biology and History, Yale University, 2017
- State Bar of California
- U.S. Patent and Trademark Office
Replace Therapeutics’ technology combines the site-specificity of CRISPR/Cas9 with the writing enzyme DNA ligase to precisely manipulate small DNA sequences. This ligase-mediated PGI (L-PGI) technology is well-suited for tens to hundreds of base pair DNA edits, complementing Tome’s flagship large DNA PGI technology, integrase-mediated PGI (I-PGI). In in vitro studies, L-PGI has demonstrated high efficiency and specificity in both dividing and non-dividing cells without the need for double-strand DNA breaks.
Under the terms of the acquisition, Tome will acquire Replace Therapeutics through a merger transaction of $65 million in up-front and near-term milestones, and a total deal value of up to $185 million through a mix of stock and cash. As a result of the merger, Replace Therapeutics will be a wholly owned subsidiary of Tome Biosciences.
The Wilson Sonsini team that advised Replace Therapeutics on the transaction included James Huie, Jason Breen, and Vishakha Negi.
For more information, please see Tome’s news release. Additional coverage is available in Endpoints News.
- Privacy Policy
- Terms of Use
- Accessibility